New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2014
08:41 EDTHEBHemispherx analysis of new data on protection from pulmonary damage by H5N1
Hemispherx Biopharma announced that Dr. William M. Mitchell of Vanderbilt University presented a research paper on January 21 at the Keystone Symposia Conference on Pathogenesis of Respiratory Viruses entitled "Protection from Pulmonary Tissue Damage Associated with Infection of Cynomolgus Macaques by Highly Pathogenic Avian Influenza Virus, or H5N1, by Low Dose Natural Human IFN-á Administered to the Buccal Mucosa." The global threat of an influenza pandemic emerging from avian H5N1 and H7N9 influenza viruses that are highly pathogenic for humans has mobilized a variety of efforts to mitigate the potential devastating human and economic consequences. The study demonstrated a dose-dependent sparing of the H5N1 induced pulmonary damage. Clinical studies will be required to validate similar results in humans from highly pathogenic H5N1, H7N9, or similar emerging avian influenza viruses. Thus, both H5N1 influenza virus (the subject of collaboration with the Osterhaus group) and H7N9 influenza virus (the subject of ongoing collaboration with Prof. J. Richt's group at the Center of Excellence for Emerging and Zoonotic Animal Diseases, Kansas State University are susceptible to Alferon N treatment in various model systems. The latter work was conducted at research facilities designed to enhance the capability of the US Department of Homeland Security.
News For HEB From The Last 14 Days
Check below for free stories on HEB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
08:44 EDTHEBHemispherx Ampligen induces cross-reactive antibody formation
Subscribe for More Information
September 10, 2014
08:35 EDTHEBHemispherx expands Ebola collaborative research agreement with governments
Hemispherx Biopharma announced that it expanded its Collaborative Research Agreement to test Alferon, the only multi-species, natural alpha interferon, or IFN, commercially approved in the U.S. and Ampligen®, an experimental drug, to be evaluated against the deadly Ebola virus also under the DEA, or Data Exchange Agreement, Annex for Medical Preparedness and Bio-Defense Agreement between the Swiss Surgeon General and the US Department of Defense. The World Health Organization has warned that "The Ebola outbreak will affect more than 20,000 people in West Africa and might spread to more countries, indicating a clinical emergency all over the world."
September 8, 2014
08:43 EDTHEBHemispherx, USAMRIID to collaborate in studying Alferon, Ampligen
Hemispherx Biopharma announced that the company and United States Army Medical Research Institute of Infectious Diseases, or USAMRIID, scientists have agreed to test Alferon, the only multi-species, natural alpha interferon, or IFN, commercially approved in the U.S. and Ampligen, an experimental drug, to be evaluated against the deadly Ebola virus, which has been and remains a major focus of efforts at USAMRIID, a unit of the Department of Defense responsible for medical biological defense research. A key component of innate immune responses is activation of the Toll-like receptors, or TLRs. TLR3 activation by dsRNA is an essential response element to viral infection. Block TLR3 activation and an essential element of the innate immune response is disarmed. Ampligen, Poly I:Poly C12U was designed as an IFN inducer and has demonstrated antiviral activity in a wide variety of DNA and RNA viruses in pre-clinical testing. Replenishing an Ebola patient's natural interferon with Alferon and restoring that patient's innate immune response by Ampligen's overcoming the Ebola blocking mechanisms could potentially reduce the morbidity and mortality of Ebola virus disease.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use